Sign up for our daily briefing
Make your busy days simpler with Axios AM/PM. Catch up on what's new and why it matters in just 5 minutes.
Stay on top of the latest market trends
Subscribe to Axios Markets for the latest market trends and economic insights. Sign up for free.
Sports news worthy of your time
Binge on the stats and stories that drive the sports world with Axios Sports. Sign up for free.
Tech news worthy of your time
Get our smart take on technology from the Valley and D.C. with Axios Login. Sign up for free.
Get the inside stories
Get an insider's guide to the new White House with Axios Sneak Peek. Sign up for free.
Catch up on coronavirus stories and special reports, curated by Mike Allen everyday
Catch up on coronavirus stories and special reports, curated by Mike Allen everyday
Want a daily digest of the top Denver news?
Get a daily digest of the most important stories affecting your hometown with Axios Denver
Want a daily digest of the top Des Moines news?
Get a daily digest of the most important stories affecting your hometown with Axios Des Moines
Want a daily digest of the top Twin Cities news?
Get a daily digest of the most important stories affecting your hometown with Axios Twin Cities
Want a daily digest of the top Tampa Bay news?
Get a daily digest of the most important stories affecting your hometown with Axios Tampa Bay
Want a daily digest of the top Charlotte news?
Get a daily digest of the most important stories affecting your hometown with Axios Charlotte
Private equity firms are snapping up dermatology practices, and at least some health care experts are not thrilled about it.
By the numbers: More than 700 dermatology practices are now owned by private equity. The number of takeovers increased 12-fold from 2012 to 2017.
What they’re saying: That rapid pace raises a lot of questions about what will happen under private equity firms’ quest for rapid growth, and the consequences once they sell, former deputy FDA commissioner Joshua Sharfstein writes in a JAMA Dermatology editorial.
- "At the current pace, by the time more is understood about the takeover of dermatology practices by private equity firms, it will likely be too late to change course. Efforts to protect the field of dermatology and the American public from the potential adverse consequences should begin now," he wrote.
Between the lines: It’s not just dermatology. Private equity firms have big health care appetites generally.
- One big difference, though: They’ve previously gravitated toward emergency services and ambulances — services that, if you need them, you’re in no position to turn them down because of the price.
- Dermatology doesn’t quite fit that bill, but it’s nevertheless a lucrative specialty.
Go deeper: Private equity's thirst for health care providers